{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280149","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.751490+00:00","generated_at":"2026-05-16T20:21:16.995034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Q3 net loss $11.8M; cash $194.9M funds operations into 2028","bullets":["Net loss of $11.8M for Q3 2025 vs. $13.2M in Q3 2024; R&D spend down to $10.1M.","Cash and marketable securities $194.9M at Sept 30, 2025; expected runway into 2028.","Preparing End-of-Phase 2 meeting request to FDA for IPF chronic cough in Q4 2025.","Phase 3 program for IPF chronic cough planned to start in H1 2026.","Phase 2b study for refractory chronic cough (RCC) also targeted for H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280149","json":"https://secwatch.observer/filing/0001193125-25-280149.json","markdown":"https://secwatch.observer/filing/0001193125-25-280149.md","text":"https://secwatch.observer/filing/0001193125-25-280149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/0001193125-25-280149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/trvi-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:21:16.995034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}